Akums Drugs & Pharmaceuticals Ltd

Akums Drugs & Pharmaceuticals Ltd has experienced a notable shift in its technical momentum, moving from a sideways trend to a mildly bearish stance. Despite a modest daily price increase, key technical indicators present a mixed picture, signalling caution for investors amid evolving market dynamics in the Pharmaceuticals & Biotechnology sector.

Akums Drugs & Pharmaceuticals Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 23 February 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 07 March 2026, providing investors with an up-to-date view of the company’s fundamentals, returns, and overall market standing.

Akums Drugs & Pharmaceuticals Ltd has experienced a notable shift in its technical momentum, moving from a mildly bullish stance to a sideways trend, reflecting a complex interplay of technical indicators. Despite a recent downgrade in its Mojo Grade from Hold to Sell, the stock’s price action and momentum oscillators reveal nuanced signals that investors should carefully analyse amid broader market volatility.

Akums Drugs & Pharmaceuticals Ltd has exhibited a notable shift in its technical momentum, transitioning from a sideways trend to a mildly bullish stance. Recent technical indicators, including MACD, Bollinger Bands, and moving averages, reveal a nuanced picture of the stock’s near-term prospects amid mixed sectoral and market returns.

Akums Drugs & Pharmaceuticals Ltd has experienced a notable shift in its technical momentum, moving from a mildly bullish stance to a sideways trend. Despite a recent downgrade in its Mojo Grade from Hold to Sell, the stock’s price action and technical indicators present a nuanced picture for investors navigating the Pharmaceuticals & Biotechnology sector.

Akums Drugs & Pharmaceuticals Ltd has recently exhibited a shift in its technical momentum, moving from a sideways trend to a mildly bullish stance. Despite a mixed bag of technical indicators, the stock’s price action and momentum metrics suggest cautious optimism for investors navigating the Pharmaceuticals & Biotechnology sector.

Akums Drugs & Pharmaceuticals Ltd has seen its investment rating downgraded from Hold to Sell, reflecting a combination of deteriorating technical indicators, flat financial performance, and subdued growth prospects. The downgrade, effective from 23 February 2026, is driven by a reassessment across four key parameters: Quality, Valuation, Financial Trend, and Technicals.

Akums Drugs & Pharmaceuticals Ltd has experienced a notable shift in its technical momentum, moving from a mildly bullish stance to a sideways trend, reflecting a complex interplay of technical indicators. Despite a recent downgrade from Hold to Sell by MarketsMOJO, the stock’s price action and momentum oscillators reveal a nuanced picture for investors navigating the Pharmaceuticals & Biotechnology sector.

Akums Drugs & Pharmaceuticals Ltd is rated 'Hold' by MarketsMOJO, with this rating last updated on 16 February 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 23 February 2026, providing investors with an up-to-date view of the company’s fundamentals, valuation, financial trends, and technical outlook.

Akums Drugs & Pharmaceuticals Ltd has exhibited a notable shift in its technical momentum, transitioning from a sideways trend to a mildly bullish stance. This change is underscored by a 5.71% gain in the stock price on 17 Feb 2026, reflecting renewed investor interest despite mixed longer-term returns compared to the broader Sensex index.

Akums Drugs & Pharmaceuticals Ltd has recently seen its quality grade upgraded from below average to average, reflecting notable improvements in key business fundamentals. This article analyses the changes in profitability, capital efficiency, debt levels, and consistency metrics that underpin this upgrade, providing investors with a comprehensive view of the company’s evolving financial health and market positioning.

Akums Drugs & Pharmaceuticals Ltd recorded a robust intraday performance on 16 Feb 2026, surging to a day’s high of Rs 487.2, marking an 8.11% rise and closing with a notable 9.62% gain. This sharp uptick outpaced the Pharmaceuticals & Biotechnology sector and the broader market indices, reflecting a significant rebound after two days of decline.

Akums Drugs & Pharmaceuticals Ltd., one of India's leading contract development and manufacturing organisations (CDMO), posted a consolidated net profit of ₹66.32 crores for Q3 FY26, marking a robust 62.63% quarter-on-quarter surge but a modest 1.75% year-on-year gain. The ₹7,159 crore market capitalisation company saw its shares decline 2.95% following the results announcement, reflecting investor concerns about the sustainability of the profit recovery despite improved operating metrics.

Akums Drugs & Pharmaceuticals Ltd is rated Strong Sell by MarketsMOJO. This rating was last updated on 17 Nov 2025, reflecting a shift from the previous 'Sell' grade. However, the analysis and financial metrics discussed here represent the stock's current position as of 12 February 2026, providing investors with an up-to-date view of the company’s fundamentals, valuation, financial trends, and technical outlook.

Akums Drugs & Pharmaceuticals Ltd has experienced a notable shift in its technical momentum, moving from a mildly bearish stance to a more sideways trend, reflecting a complex interplay of bullish and bearish signals across key indicators. Despite a modest day gain of 0.31%, the stock remains under pressure with a strong sell rating, underscoring the challenges facing this small-cap pharmaceutical player amid broader market dynamics.